Transcatheter valve-in-valve or valve-in-ring implantation with a novel balloon-expandable device in patients with bioprosthetic left side heart valves failure: 1-year follow-up from a multicenter experience

医学 心脏病学 内科学 心力衰竭 二尖瓣 气球 主动脉瓣 外科 心脏瓣膜
作者
Elisabetta Moscarella,Alfonso Ielasi,Abdurashid Mussayev,Matteo Montorfano,Ajit Mullassari,Pedro Martin,Luca Testa,John Jose,Vlasis Ninios,Kostantinos Toutouzas,Francesco Giannini,Attila Kertesz,Daniel Unic,Henrik Nissen,Babu Ezhumalai,Nagendra Boopathy,Ignacio Amat-Santos,Ashok Seth,Francesco Bedogni,Maurizio Tespili
出处
期刊:International Journal of Cardiology [Elsevier BV]
标识
DOI:10.1016/j.ijcard.2023.01.017
摘要

Transcatheter aortic and mitral valve-in-valve (ViV) or valve-in-ring (ViR) implantation into failed bioprosthetic heart valves (BHVs) or rings represents an appealing, less invasive, treatment option for patients at high surgical risk. Nowadays, few data have been reported on the use of balloon-expandable Myval (Meril Life Science, Vapi, India) transcatheter heart valve (THV) for the treatment of degenerated BHVs or rings. We aimed at evaluating the early and mid-term clinical outcomes of patients with left side heart bioprosthesis deterioration treated with transcatheter ViV/ViR implantation using Myval THV.97 consecutive patients with symptomatic, severe aortic(n=33) and mitral(n=64) BHVs/ring dysfunction underwent transcatheter aortic ViV and mitral ViV/ViR implantation with Myval THV.Technical success was achieved in 95 (98%) of the patients. Two cases of acute structural trans-catheter mitral ViV/ViR dysfunction requiring a second THV implantation were reported. At 30-day, a significant reduction in prosthetic trans-valvular pressure gradients and increase in valve areas were seen following both aortic and mitral ViV/ViR implantation. Overall survival at 15 months (IQR 8-21) was 92%. Patients undergoing mitral ViV/ViR had a relatively worse survival compared with those undergoing aortic ViV implantation (89% vs. 97% respectively; HR:2.7,CI:0.33-22.7;p=0.34). At longest follow-up available a significant improvement in NYHA functional class I and II was observed in patients with aortic and mitral ViV/ViR implantation(93.8% and 92.1%).Despite high surgical risk, transcatheter ViV/ViR implantation for failed left side heart bioprosthesis can be performed safely using Myval THV with a high success rate and low early and mid-term mortality and morbidity.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
吴洲凤完成签到,获得积分10
刚刚
hbutsj完成签到,获得积分10
刚刚
pp完成签到,获得积分10
刚刚
zzjjss发布了新的文献求助10
刚刚
极限001的应助被xjt采纳,获得100
刚刚
小懿发布了新的文献求助10
1秒前
1秒前
1秒前
呱呱完成签到,获得积分10
2秒前
温衡发布了新的文献求助10
2秒前
aANDb完成签到,获得积分10
2秒前
杨欢喜发布了新的文献求助10
2秒前
歪比巴卜完成签到,获得积分20
2秒前
2秒前
磊磊磊发布了新的文献求助10
2秒前
3秒前
3秒前
田智友发布了新的文献求助10
3秒前
科研顺利完成签到 ,获得积分10
3秒前
3秒前
3秒前
ccccyyy发布了新的文献求助10
4秒前
4秒前
含蓄凝安完成签到,获得积分10
4秒前
同城代打完成签到,获得积分10
4秒前
5秒前
CodeCraft的应助被zzjjss采纳,获得10
5秒前
marinzou发布了新的文献求助10
6秒前
李元完成签到,获得积分10
6秒前
LLIII完成签到 ,获得积分10
6秒前
6秒前
h11的应助被ililiiris采纳,获得10
6秒前
6秒前
6秒前
momo完成签到,获得积分10
6秒前
tian完成签到,获得积分10
7秒前
吃进负熵给吃进负熵的求助进行了留言
7秒前
可可发布了新的文献求助10
7秒前
7秒前
liangjiabin1234完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159663
求助须知:如何正确求助?哪些是违规求助? 9555211
关于积分的说明 21725494
捐赠科研通 7749713
什么是DOI,文献DOI怎么找? 3427292
关于科研通互助平台的介绍 2552372
邀请新用户注册赠送积分活动 2471628